Related Experiment Video
Updated: Dec 29, 2025

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade
Published on: August 14, 2019
Dietary flavonols and risk of Alzheimer dementia
Thomas M Holland1, Puja Agarwal2, Yamin Wang2
1From Rush Institute for Healthy Aging (T.M.H., P.A., Y.W., M.C.M.), Rush Alzheimer's Disease Center (S.E.L., D.A.B.), and Neurological Sciences (S.E.L., D.A.B.), Rush University Medical Center, Chicago, IL; and Jean Mayer USDA Human Nutrition Research Center on Aging (S.L.B.), Tufts University, Boston, MA. thomas_holland@rush.edu.
Objective:
To determine whether dietary intake of flavonols is associated with Alzheimer dementia.
Methods:
The study was conducted among 921 participants of the Rush Memory and Aging Project (MAP), an ongoing community-based, prospective cohort. Participants completed annual neurologic evaluations and dietary assessments using a validated food frequency questionnaire.
Results:
Among 921 MAP participants who initially had no dementia in the analyzed sample, 220 developed Alzheimer dementia. The mean age of the sample was 81.2 years (SD 7.2), with the majority (n = 691, 75%) being female. Participants with the highest intake of total flavonols had higher levels of education and more participation in physical and cognitive activities. In Cox proportional hazards models, dietary intakes of flavonols were inversely associated with incident Alzheimer dementia in models adjusted for age, sex, education, APOE ɛ4, and participation in cognitive and physical activities. Hazard ratios (HRs) for the fifth vs first quintiles of intake were as follows: for total flavonol, 0.52 (95% confidence interval [CI], 0.33-0.84); for kaempferol, 0.49 (95% CI, 0.31-0.77); for myricetin, 0.62 (95% CI, 0.4-0.97); and for isorhamnetin, 0.62 (95% CI, 0.39-0.98). Quercetin was not associated with Alzheimer dementia (HR, 0.69; 95% CI, 0.43-1.09).
Conclusion:
Higher dietary intakes of flavonols may be associated with reduced risk of developing Alzheimer dementia.
Related Concept Videos
Cancer Prevention
Some...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....
Pharmacodynamics in Geriatric Patients: Effects of Age
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

